UCB S.A.

UCB is a global biopharmaceutical company headquartered in Brussels, Belgium, dedicated to the discovery and development of innovative medicines and solutions. Its core mission is to create value for people living with severe diseases by advancing science and embracing new knowledge, particularly within the fields of immunology and neurology.

The company's focus areas include severe diseases of the immune system and central nervous system. Key products in its portfolio address conditions such as epilepsy, Parkinson's disease, Crohn's disease, plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and myasthenia gravis. Notable medicines include CIMZIA®, VIMPAT®, KEPPRA®, BIMZELX®, EVENITY®, FINTEPLA®, RYSTIGGO®, and ZILBRYSQ®. UCB also offers patient support services through UCBCares®.

UCB maintains a strong market position within the biopharmaceutical sector, driven by significant investment in research and development, which represents nearly 30% of its revenue. Jean-Christophe Tellier serves as the CEO. Recent strategic moves include the acquisition of IMIDomics' Patient Insight Business in May 2026 to enhance capabilities in immune-mediated inflammatory diseases, and the acquisition of Neurona Therapeutics in April 2026 to advance epilepsy treatments. The company reported a revenue of €7.7 billion in 2025.